Medicskin Holdings Ltd.

As of September 30, 2023, Medicskin Holdings Ltd. carries a market capitalization of 82.52M, placing it among publicly traded companies globally. Its enterprise value stands at 84.24M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2023, Medicskin Holdings Ltd. has 396.74M shares outstanding.

These figures are as of September 30, 2023. The price-to-sales ratio is 1.65, and the price-to-book ratio stands at 6.67.

As of September 30, 2023, Medicskin Holdings Ltd. trades at an EV/EBITDA multiple of 5.45 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.68 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.89 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 84.24M versus a market cap of 82.52M, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2023, Medicskin Holdings Ltd. maintains a current ratio of 0.87, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 104.11, indicating elevated leverage, while an interest coverage ratio of 23.60 demonstrates strong ability to service its debt obligations.

Over the twelve months ended September 30, 2023, Medicskin Holdings Ltd. posted a negative return on equity (ROE) of -13.53, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.04, reflecting losses generated across the asset base. The company generates approximately 1.18M in revenue per employee across its workforce of 42.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.80 indicates how many times Medicskin Holdings Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended September 30, 2023, Medicskin Holdings Ltd. recorded an income tax benefit of -2,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -1.84M and -1.79M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Medicskin Holdings Ltd.'s stock has declined approximately 15.44% over the past 52 weeks. The 50-day moving average sits at 0.14, while the 200-day moving average is 0.17.

Over the twelve months ended September 30, 2023, Medicskin Holdings Ltd. generated 50.08M in revenue and converted that into -1.79M in net income, yielding earnings per share of 0.00. EBITDA reached 15.46M, while operating income came in at 6.07M.

As of September 30, 2023, Medicskin Holdings Ltd. holds 4.35M in cash and equivalents against 9.41M in total debt, resulting in a net debt position of -3.35M. Total book value stands at 12.37M, with working capital of -3.77M providing operational flexibility.

Over the twelve months ended September 30, 2023, Medicskin Holdings Ltd. posted a gross margin of 79.98, reflecting its pricing power and cost economics. The operating margin of 12.12 and net profit margin of -3.58 provide insight into operational efficiency.

As of September 30, 2023, Medicskin Holdings Ltd. has an Altman Z-Score of 3.15, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.